Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FAMOTIDINE

14 general benefit · 2 not a benefit

Other products in the same Health Canada class (A02B, A02BA) — coverage varies; not interchangeable

  • Cimetidine (Cimetidine): general benefit, Not a benefit
  • Nizatidine (Axid): general benefit
  • Ranitidine (Zantac): general benefit, Not a benefit
  • Misoprostol (Cytotec): general benefit, Not a benefit
  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit

7 more in the class list below

AG-Famotidine · DIN 02509970 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AG-Famotidine · DIN 02509970 Manufacturer: Angita Pharma Inc.; listing date 2021-12-17 Health Canada: Marketed since 2021-09-21 · brand AG-FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 20 MG · company Angita pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

AG-Famotidine: Formulary list price $0.2658/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2658 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99923 · Verify on the e-Formulary ↗ (DIN 02509970)

Source record
DIN 02509970: AG-Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000025; group id 678; item number 1693; lccId None; manufacturer id ANG Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2658; ministry $0.2658 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02509970 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99923
Interchangeable products
Apo-Famotidine · DIN 01953842 · $0.2658 Famotidine · DIN 02351102 · $0.2658 Famotidine · DIN 02549107 · $0.2658 Jamp Famotidine · DIN 02507749 · $0.2658 Mint-Famotidine · DIN 02538628 · $0.2658 Pepcid · DIN 00710121 · not recorded Teva-Famotidine · DIN 02022133 · $0.2658
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509970
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Famotidine · DIN 02351102 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Famotidine · DIN 02351102 Manufacturer: Sanis Health Inc.; listing date 2011-12-15 Health Canada: Marketed since 2024-10-24 · brand FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 20 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Famotidine: Formulary list price $0.2658/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2658 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83631 · Verify on the e-Formulary ↗ (DIN 02351102)

Source record
DIN 02351102: Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000025; group id 678; item number 1693; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2658; ministry $0.2658 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351102 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83631
Interchangeable products
AG-Famotidine · DIN 02509970 · $0.2658 Apo-Famotidine · DIN 01953842 · $0.2658 Famotidine · DIN 02549107 · $0.2658 Jamp Famotidine · DIN 02507749 · $0.2658 Mint-Famotidine · DIN 02538628 · $0.2658 Pepcid · DIN 00710121 · not recorded Teva-Famotidine · DIN 02022133 · $0.2658
Shortage status: anticipated shortage (last updated 2026-05-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02351102
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Famotidine · DIN 02549107 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Famotidine · DIN 02549107 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2025-01-31 Health Canada: Marketed since 2024-11-13 · brand FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Famotidine: Formulary list price $0.2658/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2658 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103798 · Verify on the e-Formulary ↗ (DIN 02549107)

Source record
DIN 02549107: Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000025; group id 678; item number 1693; lccId None; manufacturer id SIV Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2658; ministry $0.2658 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549107 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103798
Interchangeable products
AG-Famotidine · DIN 02509970 · $0.2658 Apo-Famotidine · DIN 01953842 · $0.2658 Famotidine · DIN 02351102 · $0.2658 Jamp Famotidine · DIN 02507749 · $0.2658 Mint-Famotidine · DIN 02538628 · $0.2658 Pepcid · DIN 00710121 · not recorded Teva-Famotidine · DIN 02022133 · $0.2658
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549107
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Famotidine · DIN 02507749 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Famotidine · DIN 02507749 Manufacturer: Jamp Pharma Corporation; listing date 2021-10-29 Health Canada: Marketed since 2021-09-21 · brand JAMP FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 20 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Famotidine: Formulary list price $0.2658/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2658 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99714 · Verify on the e-Formulary ↗ (DIN 02507749)

Source record
DIN 02507749: Jamp Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000025; group id 678; item number 1693; lccId None; manufacturer id JPC Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2658; ministry $0.2658 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02507749 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99714
Interchangeable products
AG-Famotidine · DIN 02509970 · $0.2658 Apo-Famotidine · DIN 01953842 · $0.2658 Famotidine · DIN 02351102 · $0.2658 Famotidine · DIN 02549107 · $0.2658 Mint-Famotidine · DIN 02538628 · $0.2658 Pepcid · DIN 00710121 · not recorded Teva-Famotidine · DIN 02022133 · $0.2658
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02507749
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Famotidine · DIN 02538628 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Famotidine · DIN 02538628 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-07-31 Health Canada: Marketed since 2024-04-30 · brand MINT-FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 20 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Famotidine: Formulary list price $0.2658/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2658 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102732 · Verify on the e-Formulary ↗ (DIN 02538628)

Source record
DIN 02538628: Mint-Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000025; group id 678; item number 1693; lccId None; manufacturer id MIN Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2658; ministry $0.2658 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538628 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102732
Interchangeable products
AG-Famotidine · DIN 02509970 · $0.2658 Apo-Famotidine · DIN 01953842 · $0.2658 Famotidine · DIN 02351102 · $0.2658 Famotidine · DIN 02549107 · $0.2658 Jamp Famotidine · DIN 02507749 · $0.2658 Pepcid · DIN 00710121 · not recorded Teva-Famotidine · DIN 02022133 · $0.2658
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538628
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Famotidine · DIN 02022133 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Famotidine · DIN 02022133 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2014-04-03 · brand TEVA-FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 20 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Famotidine: Formulary list price $0.2658/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2658 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13654 · Verify on the e-Formulary ↗ (DIN 02022133)

Source record
DIN 02022133: Teva-Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000025; group id 678; item number 1693; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2658; ministry $0.2658 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02022133 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13654
Interchangeable products
AG-Famotidine · DIN 02509970 · $0.2658 Apo-Famotidine · DIN 01953842 · $0.2658 Famotidine · DIN 02351102 · $0.2658 Famotidine · DIN 02549107 · $0.2658 Jamp Famotidine · DIN 02507749 · $0.2658 Mint-Famotidine · DIN 02538628 · $0.2658 Pepcid · DIN 00710121 · not recorded
Shortage status: resolved shortage (ended 2026-02-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02022133
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AG-Famotidine · DIN 02509989 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AG-Famotidine · DIN 02509989 Manufacturer: Angita Pharma Inc.; listing date 2021-12-17 Health Canada: Marketed since 2021-09-21 · brand AG-FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 40 MG · company Angita pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

AG-Famotidine: Formulary list price $0.4834/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4834 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99924 · Verify on the e-Formulary ↗ (DIN 02509989)

Source record
DIN 02509989: AG-Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000024; group id 678; item number 1694; lccId None; manufacturer id ANG Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4834; ministry $0.4834 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02509989 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99924
Interchangeable products
Apo-Famotidine · DIN 01953834 · $0.4834 Famotidine · DIN 02351110 · $0.4834 Famotidine · DIN 02549115 · $0.4834 Jamp Famotidine · DIN 02507757 · $0.4834 Mint-Famotidine · DIN 02538636 · $0.4834 Pepcid · DIN 00710113 · not recorded Teva-Famotidine · DIN 02022141 · $0.4834
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509989
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Famotidine · DIN 02351110 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Famotidine · DIN 02351110 Manufacturer: Sanis Health Inc.; listing date 2011-12-15 Health Canada: Marketed since 2024-10-24 · brand FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 40 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Famotidine: Formulary list price $0.4834/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4834 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83632 · Verify on the e-Formulary ↗ (DIN 02351110)

Source record
DIN 02351110: Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000024; group id 678; item number 1694; lccId None; manufacturer id SAI Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4834; ministry $0.4834 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351110 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83632
Interchangeable products
AG-Famotidine · DIN 02509989 · $0.4834 Apo-Famotidine · DIN 01953834 · $0.4834 Famotidine · DIN 02549115 · $0.4834 Jamp Famotidine · DIN 02507757 · $0.4834 Mint-Famotidine · DIN 02538636 · $0.4834 Pepcid · DIN 00710113 · not recorded Teva-Famotidine · DIN 02022141 · $0.4834
Shortage status: resolved shortage (ended 2024-03-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02351110
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Famotidine · DIN 02549115 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Famotidine · DIN 02549115 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2025-01-31 Health Canada: Marketed since 2024-11-13 · brand FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 40 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Famotidine: Formulary list price $0.4834/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4834 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103799 · Verify on the e-Formulary ↗ (DIN 02549115)

Source record
DIN 02549115: Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000024; group id 678; item number 1694; lccId None; manufacturer id SIV Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4834; ministry $0.4834 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549115 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103799
Interchangeable products
AG-Famotidine · DIN 02509989 · $0.4834 Apo-Famotidine · DIN 01953834 · $0.4834 Famotidine · DIN 02351110 · $0.4834 Jamp Famotidine · DIN 02507757 · $0.4834 Mint-Famotidine · DIN 02538636 · $0.4834 Pepcid · DIN 00710113 · not recorded Teva-Famotidine · DIN 02022141 · $0.4834
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549115
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Famotidine · DIN 02507757 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Famotidine · DIN 02507757 Manufacturer: Jamp Pharma Corporation; listing date 2021-10-29 Health Canada: Marketed since 2021-09-17 · brand JAMP FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 40 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Famotidine: Formulary list price $0.4834/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4834 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99715 · Verify on the e-Formulary ↗ (DIN 02507757)

Source record
DIN 02507757: Jamp Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000024; group id 678; item number 1694; lccId None; manufacturer id JPC Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4834; ministry $0.4834 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02507757 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99715
Interchangeable products
AG-Famotidine · DIN 02509989 · $0.4834 Apo-Famotidine · DIN 01953834 · $0.4834 Famotidine · DIN 02351110 · $0.4834 Famotidine · DIN 02549115 · $0.4834 Mint-Famotidine · DIN 02538636 · $0.4834 Pepcid · DIN 00710113 · not recorded Teva-Famotidine · DIN 02022141 · $0.4834
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02507757
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Famotidine · DIN 02538636 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Famotidine · DIN 02538636 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-07-31 Health Canada: Marketed since 2024-04-30 · brand MINT-FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 40 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Famotidine: Formulary list price $0.4834/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4834 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102733 · Verify on the e-Formulary ↗ (DIN 02538636)

Source record
DIN 02538636: Mint-Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000024; group id 678; item number 1694; lccId None; manufacturer id MIN Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4834; ministry $0.4834 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538636 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102733
Interchangeable products
AG-Famotidine · DIN 02509989 · $0.4834 Apo-Famotidine · DIN 01953834 · $0.4834 Famotidine · DIN 02351110 · $0.4834 Famotidine · DIN 02549115 · $0.4834 Jamp Famotidine · DIN 02507757 · $0.4834 Pepcid · DIN 00710113 · not recorded Teva-Famotidine · DIN 02022141 · $0.4834
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538636
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Famotidine · DIN 02022141 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Famotidine · DIN 02022141 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2014-04-03 · brand TEVA-FAMOTIDINE · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 40 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Famotidine: Formulary list price $0.4834/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4834 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13655 · Verify on the e-Formulary ↗ (DIN 02022141)

Source record
DIN 02022141: Teva-Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000024; group id 678; item number 1694; lccId None; manufacturer id TEV Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4834; ministry $0.4834 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02022141 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13655
Interchangeable products
AG-Famotidine · DIN 02509989 · $0.4834 Apo-Famotidine · DIN 01953834 · $0.4834 Famotidine · DIN 02351110 · $0.4834 Famotidine · DIN 02549115 · $0.4834 Jamp Famotidine · DIN 02507757 · $0.4834 Mint-Famotidine · DIN 02538636 · $0.4834 Pepcid · DIN 00710113 · not recorded
Shortage status: resolved shortage (ended 2026-02-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02022141
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Famotidine · DIN 01953842 · 20mg · tablet

General benefitDormant since 2017-08-04 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Famotidine · DIN 01953842 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Dormant since 2017-08-04 · brand APO-FAMOTIDINE TAB 20MG USP · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 20 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Famotidine: Formulary list price $0.2658/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2658 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13572 · Verify on the e-Formulary ↗ (DIN 01953842)

Source record
DIN 01953842: Apo-Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000025; group id 678; item number 1693; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2658; ministry $0.2658 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01953842 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13572
Interchangeable products
AG-Famotidine · DIN 02509970 · $0.2658 Famotidine · DIN 02351102 · $0.2658 Famotidine · DIN 02549107 · $0.2658 Jamp Famotidine · DIN 02507749 · $0.2658 Mint-Famotidine · DIN 02538628 · $0.2658 Pepcid · DIN 00710121 · not recorded Teva-Famotidine · DIN 02022133 · $0.2658
Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01953842
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2017-08-04 — choose a marketed DIN from the same-category list.

Apo-Famotidine · DIN 01953834 · 40mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.Discontinued 2024-07-21 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Famotidine · DIN 01953834 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2024-07-21 · brand APO-FAMOTIDINE TAB 40MG USP · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 40 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Famotidine: Formulary list price $0.4834/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4834 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13583 · Verify on the e-Formulary ↗ (DIN 01953834)

Source record
DIN 01953834: Apo-Famotidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000024; group id 678; item number 1694; lccId None; manufacturer id APX Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4834; ministry $0.4834 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01953834 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13583
Interchangeable products
AG-Famotidine · DIN 02509989 · $0.4834 Famotidine · DIN 02351110 · $0.4834 Famotidine · DIN 02549115 · $0.4834 Jamp Famotidine · DIN 02507757 · $0.4834 Mint-Famotidine · DIN 02538636 · $0.4834 Pepcid · DIN 00710113 · not recorded Teva-Famotidine · DIN 02022141 · $0.4834
Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01953834
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.

Pepcid · DIN 00710121 · 20mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-15 — choose a marketed DIN from the same-category list.Discontinued 2013-07-15 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-15 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2013-07-15 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pepcid · DIN 00710121 Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 2013-07-15 · brand PEPCID TAB 20MG · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 20 MG · company Merck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Pepcid: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7087 · Verify on the e-Formulary ↗ (DIN 00710121)

Source record
DIN 00710121: Pepcid Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 564000025; group id 678; item number 1693; lccId None; manufacturer id MFC Source form: Tab; strength: 20mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00710121 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7087
Interchangeable products
AG-Famotidine · DIN 02509970 · $0.2658 Apo-Famotidine · DIN 01953842 · $0.2658 Famotidine · DIN 02351102 · $0.2658 Famotidine · DIN 02549107 · $0.2658 Jamp Famotidine · DIN 02507749 · $0.2658 Mint-Famotidine · DIN 02538628 · $0.2658 Teva-Famotidine · DIN 02022133 · $0.2658
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00710121
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2013-07-15 — choose a marketed DIN from the same-category list.

Pepcid · DIN 00710113 · 40mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-15 — choose a marketed DIN from the same-category list.Discontinued 2013-07-15 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-15 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2013-07-15 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pepcid · DIN 00710113 Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 2013-07-15 · brand PEPCID TAB 40MG · ATC A02BA03 FAMOTIDINE · form Tablet · route Oral · ingredients FAMOTIDINE 40 MG · company Merck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Pepcid: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7088 · Verify on the e-Formulary ↗ (DIN 00710113)

Source record
DIN 00710113: Pepcid Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 564000024; group id 678; item number 1694; lccId None; manufacturer id MFC Source form: Tab; strength: 40mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00710113 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7088
Interchangeable products
AG-Famotidine · DIN 02509989 · $0.4834 Apo-Famotidine · DIN 01953834 · $0.4834 Famotidine · DIN 02351110 · $0.4834 Famotidine · DIN 02549115 · $0.4834 Jamp Famotidine · DIN 02507757 · $0.4834 Mint-Famotidine · DIN 02538636 · $0.4834 Teva-Famotidine · DIN 02022141 · $0.4834
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00710113
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2013-07-15 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN

· 2 products · Listed, not a benefit (1), Limited Use, codes 306, 307 (1) · strengths: 30mg & 500mg & 500mg · Tab/Cap Pk

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-FAMOTIDINE is indicated in the treatment of the following conditions where a controlled reduction of gastric secretion is required: 1. Treatment of acute duodenal ulcer; 2. Prophylactic use in duodenal ulcer; 3. Treatment of acute benign gastric ulcer; 4. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome) 5. Treatment of gastroesophageal reflux disease (GERD); 6. Maintenance of remission of patients with GERD. https://pdf.hres.ca/dpd_pm/00062204.PDF PM date: July 20, 2021 Source product: TEVA-FAMOTIDINE; DIN 02022133; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Famotidine · DIN 01953842 Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01953842

Check this DIN again

Apo-Famotidine · DIN 01953834 Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01953834

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Pepcid: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026